Verifying the effectiveness of romosozumab re-administration on bone mineral density
Authors' conclusion
In conclusion, romosozumab re-administration is an effective treatment. Furthermore, its efficacy varies depending on the sequential therapy used, with the highest effectiveness seen in the order of teriparatide, bisphosphonates, and denosumab.
Study context
- Population
- Osteoporosis patients who remained at high fracture risk after a 12-mo course of romosozumab followed by sequential therapy (bisphosphonates, denosumab or teriparatide), re-administered another 12-mo romosozumab
- Participants
- 72 patients
- Comparison
- Romosozumab re-administration after sequential therapy
- Outcome
- Changes in BMD and percentages of patients achieving a T-score > −2.5
- Follow-up
- Completion of 12-mo re-administration
Main finding
As reported in the abstract
12-mo re-administration
- Bone mineral density (BMD) at lumbar spine and femoral neck increased significantly through re-administration
- p < .001
- Patients achieving T-score > −2.5 in lumbar spine, total hip and femoral neck increased significantly vs before initial romosozumab, greatest after re-administration
- all p < .001
Further findings
Bone turnover markers · during re-administration
- Bone formation markers increased significantly
- P < 0.001
- Resorption markers showed no significant change
- P = 0.408
BMD by prior sequential therapy
- Bisphosphonates: BMD increased significantly at all sites
- P < 0.05
- Denosumab: significant BMD increase only in lumbar spine; total hip and femoral neck no significant change
- P < 0.01
- Teriparatide: BMD temporarily decreased during sequential period, then increased significantly after re-administration, especially lumbar spine and femoral neck
- both p < .001
Original publication
Verifying the effectiveness of romosozumab re-administration on bone mineral density. J Bone Miner Res. Published 6 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →